Details of Disease

General Information of Disease (ID: DISOZOR8)

Disease Name	Meningioma tumour
Synonyms	meningothelial tumour; meningothelial tumor; meningeal neoplasm; meningeal neoplasms; tumor of meningeal cluster; tumour of the meninges; tumour of meningeal cluster; tumor of the meninges; meningeal tumor; meningeal cluster neoplasm; meninges neoplasm; neoplasm of the meninges; meninges tumor; meningeal cluster rare nervous system tumor; meningeal tumour; neoplasm of meningeal cluster; neoplasm of meninges; meninges tumour; tumor of meninges; meningeal cluster neoplasm (disease); meningeal cluster tumour; meningeal cluster tumor; meningeal cluster rare nervous system tumour
Disease Class	2A01: Meningioma
Definition	A benign or malignant neoplasm that affects the meninges. The majority of the neoplasms arise from meningothelial cells and are called meningiomas. Non-meningothelial cell neoplasms include mesenchymal, non-meningothelial tumors, hemangiopericytomas, and melanocytic lesions.
Disease Hierarchy	DISTBY9Z: Tumour DISFC18W: Central nervous system neoplasm DISOZOR8: Meningioma tumour
ICD Code	ICD-11 ICD-11: 2A01 Expand ICD-11 '2A01.0Z
Disease Identifiers	MONDO ID MONDO_0016743 MESH ID D008577 UMLS CUI C0025284 MedGen ID 44353 Orphanet ID 252025 SNOMED CT ID 126965008

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PMID27998201-Compound-24	DM25BNZ	Patented	Small molecular drug	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 1 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
AOX1	TT3MOS2	Limited	Altered Expression	[2]
------------------------------------------------------------------------------------

This Disease Is Related to 2 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
NENF	OTGL7MHB	Strong	Biomarker	[3]
RAD54L	OTEGMAKG	Strong	Genetic Variation	[4]
------------------------------------------------------------------------------------

References

1	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
2	Expression Profile of Genes Related to Drug Metabolism in Human Brain Tumors.PLoS One. 2015 Nov 18;10(11):e0143285. doi: 10.1371/journal.pone.0143285. eCollection 2015.
3	Serum and cerebrospinal fluid Neudesin concentration and Neudesin Quotient as potential circulating biomarkers of a primary brain tumor.BMC Cancer. 2019 Apr 5;19(1):319. doi: 10.1186/s12885-019-5525-4.
4	Search for mutations of the hRAD54 gene in sporadic meningiomas with deletion at 1p32.Mol Carcinog. 1999 Apr;24(4):300-4. doi: 10.1002/(sici)1098-2744(199904)24:4<300::aid-mc8>3.0.co;2-g.